5,281 Shares in Dr. Reddy’s Laboratories Ltd (RDY) Purchased by Airain ltd

Airain ltd purchased a new position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,281 shares of the company’s stock, valued at approximately $223,000.

Other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Dr. Reddy’s Laboratories during the 2nd quarter worth $144,000. DekaBank Deutsche Girozentrale bought a new stake in Dr. Reddy’s Laboratories during the 2nd quarter worth $237,000. Bank of New York Mellon Corp bought a new stake in Dr. Reddy’s Laboratories during the 1st quarter worth $297,000. OLD Mutual Customised Solutions Proprietary Ltd. grew its position in Dr. Reddy’s Laboratories by 41.8% during the 1st quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 7,800 shares of the company’s stock worth $313,000 after acquiring an additional 2,300 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Dr. Reddy’s Laboratories during the 2nd quarter worth $329,000. 15.30% of the stock is owned by institutional investors.

Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) opened at 33.36 on Monday. Dr. Reddy’s Laboratories Ltd has a 12 month low of $29.83 and a 12 month high of $50.10. The company has a market cap of $5.53 billion, a price-to-earnings ratio of 31.29 and a beta of 0.34. The company’s 50-day moving average price is $34.06 and its 200-day moving average price is $39.30.

RDY has been the topic of a number of research reports. CLSA upgraded Dr. Reddy’s Laboratories from an “underperform” rating to an “outperform” rating in a research report on Thursday, August 31st. Deutsche Bank AG upgraded Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. BidaskClub lowered Dr. Reddy’s Laboratories from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Zacks Investment Research upgraded Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, July 14th. Finally, Jefferies Group LLC restated a “sell” rating and set a $31.62 price objective on shares of Dr. Reddy’s Laboratories in a research report on Sunday, September 3rd. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $31.62.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2017/09/11/5281-shares-in-dr-reddys-laboratories-ltd-rdy-purchased-by-airain-ltd.html.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Institutional Ownership by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply